{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:50:46Z","timestamp":1791669046785,"version":"4.3.4"},"reference-count":189,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Program for Science & Technology of Henan Province","award":["252102311056"],"award-info":[{"award-number":["252102311056"]}]},{"name":"Key Program for Science & Technology of Henan Province","award":["262102310168, 252102310063"],"award-info":[{"award-number":["262102310168, 252102310063"]}]},{"name":"Key Program for Science & Technology of Henan Province","award":["262102310107"],"award-info":[{"award-number":["262102310107"]}]},{"name":"Province and Ministry Co-construction Program for Medical Science & Technology of Henan Province","award":["LHGJ20250763"],"award-info":[{"award-number":["LHGJ20250763"]}]},{"name":"Development Program for Science & Technology of Kaifeng City","award":["2403091"],"award-info":[{"award-number":["2403091"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer (PCa) is the second leading cause of cancer-related death among men worldwide. Although androgen deprivation therapy (ADT) effectively suppresses tumor growth, most patients eventually progress to castration-resistant prostate cancer (CRPC) and develop metastatic disease. The self-renewal, lineage plasticity, epithelial\u2013mesenchymal transition (EMT), and bone metastatic capacity of prostate cancer stem cells (PCSCs) are central drivers of CRPC progression, therapeutic resistance, and metastasis, and the aberrant activation of the canonical Wnt signaling pathway plays a key regulatory role in this process. This review systematically discusses PCSC markers and their applications in clinical diagnosis, elucidates the molecular mechanisms by which aberrant activation of the canonical Wnt signaling pathway, induced by the synergistic effects of genetic mutations, non-coding RNA (ncRNA) dysregulation, epigenetic dysregulation, tumor microenvironment (TME) alterations, and synergistic crosstalk with androgen receptor (AR) signaling, PI3K\/AKT\/mTOR signaling, Hippo\u2013YAP\/TAZ signaling, and metabolic reprogramming, enhances the stemness of PCSCs and promotes their EMT and bone metastasis. We also summarize current research on therapeutic agents targeting the canonical Wnt signaling pathway to suppress PCSCs, along with major challenges in clinical translation and potential strategies to overcome them. Collectively, we propose that targeting this pathway to inhibit PCSCs represents a highly promising strategy for controlling CRPC progression, overcoming therapeutic resistance, and ultimately improving patient outcomes.<\/jats:p>","DOI":"10.1186\/s12967-026-08751-5","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:14:48Z","timestamp":1785518088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Canonical Wnt signaling in the regulation of prostate cancer stem cells: a key driver of castration-resistant prostate cancer and a therapeutic opportunity"],"prefix":"10.1186","volume":"24","author":[{"given":"Haoze","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhui","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8117-4616","authenticated-orcid":false,"given":"Xiaobo","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4023-2137","authenticated-orcid":false,"given":"Junqing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"8751_CR1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, Bray F, Jemal A. Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update. Eur Urol. 2025;87:302\u201313.","journal-title":"Eur Urol"},{"key":"8751_CR2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S1470-2045(26)00061-6","volume":"27","author":"ZJ Ward","year":"2026","unstructured":"Ward ZJ, Moraes FY, Scott AM, Ngwa W, Loehrer PJ, Hricak H. Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers. Lancet Oncol. 2026;27:560\u20138.","journal-title":"Lancet Oncol"},{"key":"8751_CR3","doi-asserted-by":"crossref","unstructured":"Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, et al. Management of patients with advanced prostate cancer. part I: intermediate-\/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer consensus conference 2022. Eur Urol. 2023;83:267\u2013293.","DOI":"10.1016\/j.eururo.2022.11.002"},{"key":"8751_CR4","doi-asserted-by":"crossref","unstructured":"Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, et al. Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023;185:178\u2013215.","DOI":"10.1016\/j.ejca.2023.02.018"},{"key":"8751_CR5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/JU.0000000000004648","volume":"214","author":"TJ Daskivich","year":"2025","unstructured":"Daskivich TJ, Stock SR, Cummings S, Masterson JM, Aronson W, Terris M, Klaassen Z, Kane C, Amling C, Cooperberg M, et al. Risks of Progression After Early Androgen Deprivation Therapy for Biochemical Recurrence After Radical Prostatectomy. J Urol. 2025;214:354\u201364.","journal-title":"J Urol"},{"key":"8751_CR6","unstructured":"Mayo Clinic Staff. Metastatic castration-resistant prostate cancer (mCRPC). https:\/\/www.mayoclinic.org\/diseases-conditions\/metastatic-castration-resistant-prostate-cancer\/survival-rates\/gnc-20593193. Accessed 22 June 2026."},{"key":"8751_CR7","doi-asserted-by":"crossref","unstructured":"Maitland NJ. Resistance to antiandrogens in prostate cancer: is it inevitable, intrinsic or induced? Cancers (Basel). 2021;13.","DOI":"10.3390\/cancers13020327"},{"key":"8751_CR8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jare.2025.09.028","volume":"84","author":"X Zhang","year":"2026","unstructured":"Zhang X, Zhang X, Bao Q, Li R, Deng X, Cao J, Wang H, Chen D, Zou Y, Tang H. Cancer stem cell plasticity in shaping drug resistance landscapes in prostate cancer. J Adv Res. 2026;84:273\u201386.","journal-title":"J Adv Res"},{"key":"8751_CR9","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.18632\/oncotarget.2953","volume":"6","author":"AP Rybak","year":"2015","unstructured":"Rybak AP, Bristow RG, Kapoor A. Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget. 2015;6:1900\u201319.","journal-title":"Oncotarget"},{"key":"8751_CR10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-020-00430-1","volume":"6","author":"HM Zhou","year":"2021","unstructured":"Zhou HM, Zhang JG, Zhang X, Li Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther. 2021;6:62.","journal-title":"Signal Transduct Target Ther"},{"key":"8751_CR11","doi-asserted-by":"crossref","unstructured":"Al Salhi Y, Sequi MB, Valenzi FM, Fuschi A, Martoccia A, Suraci PP, Carbone A, Tema G, Lombardo R, Cicione A, et al. Cancer stem cells and prostate cancer: a narrative review. Int J Mol Sci. 2023;24.","DOI":"10.3390\/ijms24097746"},{"key":"8751_CR12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.20892\/j.issn.2095-3941.2025.0149","volume":"22","author":"L Zhang","year":"2025","unstructured":"Zhang L, Fu J, Liu X, Feng S, Leng Y. The immune landscape of systemic inflammation in prostate cancer. Cancer Biol Med. 2025;22:881\u2013902.","journal-title":"Cancer Biol Med"},{"issue":"3","key":"8751_CR13","first-page":"e176","volume":"2022","author":"W Manni","year":"2020","unstructured":"Manni W. W <>Min 2020 Signaling pathways in the regulation of cancer stem cells and associated targeted therapy. MedComm 2022 3 e176.","journal-title":"MedComm"},{"key":"8751_CR14","doi-asserted-by":"crossref","unstructured":"Khurana N, Sikka SC. Interplay between SOX9, Wnt\/\u03b2-catenin and androgen receptor signaling in castration-resistant prostate cancer. Int J Mol Sci. 2019;20.","DOI":"10.3390\/ijms20092066"},{"key":"8751_CR15","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1186\/s12967-025-07053-6","volume":"23","author":"H Xu","year":"2025","unstructured":"Xu H, Hou Y, Zhao Z, Zhang J, Li P, Cao Y, Nie X, Hou J. CBP\/p300, a promising therapeutic target for prostate cancer. J Transl Med. 2025;23:1045.","journal-title":"J Transl Med"},{"key":"8751_CR16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/07853890.2023.2166981","volume":"55","author":"Z He","year":"2023","unstructured":"He Z, Zhang J, Ma J, Zhao L, Jin X, Li H. R-spondin family biology and emerging linkages to cancer. Ann Med. 2023;55:428\u201346.","journal-title":"Ann Med"},{"key":"8751_CR17","doi-asserted-by":"crossref","first-page":"12149","DOI":"10.1074\/jbc.RA118.002918","volume":"293","author":"S Patel","year":"2018","unstructured":"Patel S, Barkell AM, Gupta D, Strong SL, Bruton S, Muskett FW, Addis PW, Renshaw PS, Slocombe PM, Doyle C, et al. Structural and functional analysis of Dickkopf 4 (Dkk4): New insights into Dkk evolution and regulation of Wnt signaling by Dkk and Kremen proteins. J Biol Chem. 2018;293:12149\u201366.","journal-title":"J Biol Chem"},{"key":"8751_CR18","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00018-022-04620-8","volume":"79","author":"DL Shi","year":"2022","unstructured":"Shi DL. Wnt\/planar cell polarity signaling controls morphogenetic movements of gastrulation and neural tube closure. Cell Mol Life Sci. 2022;79:586.","journal-title":"Cell Mol Life Sci"},{"key":"8751_CR19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3892\/ijmm.2011.632","volume":"27","author":"Y Yuan","year":"2011","unstructured":"Yuan Y, Niu CC, Deng G, Li ZQ, Pan J, Zhao C, Yang ZL, Si WK. The Wnt5a\/Ror2 noncanonical signaling pathway inhibits canonical Wnt signaling in K562 cells. Int J Mol Med. 2011;27:63\u20139.","journal-title":"Int J Mol Med"},{"key":"8751_CR20","doi-asserted-by":"crossref","first-page":"15436","DOI":"10.1073\/pnas.0704747104","volume":"104","author":"MJ Nemeth","year":"2007","unstructured":"Nemeth MJ, Topol L, Anderson SM, Yang Y, Bodine DM. Wnt5a inhibits canonical Wnt signaling in hematopoietic stem cells and enhances repopulation. Proc Natl Acad Sci U S A. 2007;104:15436\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8751_CR21","doi-asserted-by":"crossref","first-page":"13049","DOI":"10.1007\/s13277-016-5263-z","volume":"37","author":"S Koushyar","year":"2016","unstructured":"Koushyar S, Grant GH, Uysal-Onganer P. The interaction of Wnt-11 and signalling cascades in prostate cancer. Tumour Biol. 2016;37:13049\u201357.","journal-title":"Tumour Biol"},{"key":"8751_CR22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.stem.2019.03.010","volume":"24","author":"X Wei","year":"2019","unstructured":"Wei X, Zhang L, Zhou Z, Kwon OJ, Zhang Y, Nguyen H, Dumpit R, True L, Nelson P, Dong B, et al. Spatially Restricted Stromal Wnt Signaling Restrains Prostate Epithelial Progenitor Growth through Direct and Indirect Mechanisms. Cell Stem Cell. 2019;24:753\u2013e768756.","journal-title":"Cell Stem Cell"},{"key":"8751_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645\u20138.","journal-title":"Nature"},{"key":"8751_CR24","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","volume":"65","author":"AT Collins","year":"2005","unstructured":"Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946\u201351.","journal-title":"Cancer Res"},{"key":"8751_CR25","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.2353\/ajpath.2010.091064","volume":"176","author":"S Sell","year":"2010","unstructured":"Sell S. On the stem cell origin of cancer. Am J Pathol. 2010;176:2584\u20132494.","journal-title":"Am J Pathol"},{"key":"8751_CR26","doi-asserted-by":"crossref","first-page":"387014","DOI":"10.1155\/2013\/387014","volume":"2013","author":"S Ohnishi","year":"2013","unstructured":"Ohnishi S, Ma N, Thanan R, Pinlaor S, Hammam O, Murata M, Kawanishi S. DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxid Med Cell Longev. 2013;2013:387014.","journal-title":"Oxid Med Cell Longev"},{"key":"8751_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12929-018-0426-4","volume":"25","author":"AZ Ayob","year":"2018","unstructured":"Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25:20.","journal-title":"J Biomed Sci"},{"key":"8751_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12935-023-03130-2","volume":"23","author":"Q Liu","year":"2023","unstructured":"Liu Q, Guo Z, Li G, Zhang Y, Liu X, Li B, Wang J, Li X. Cancer stem cells and their niche in cancer progression and therapy. Cancer Cell Int. 2023;23:305.","journal-title":"Cancer Cell Int"},{"key":"8751_CR29","doi-asserted-by":"crossref","unstructured":"Drysch A, Ahuja A, Prasad D, Jain R, Romanos S, Alwakeal A, Ahuja C. Transcriptomic comparisons of somatic and cancer stem cells. Biomedicines. 2025;13.","DOI":"10.3390\/biomedicines13082039"},{"key":"8751_CR30","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/stmcls\/sxae025","volume":"42","author":"ML Beshiri","year":"2024","unstructured":"Beshiri ML, Capaldo BJ, Lake R, Ku AT, Burner D, Tice CM, Tran C, Kostas J, Alilin AN, Yin J, et al. Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate-resistant prostate cancer. Stem Cells. 2024;42:526\u201339.","journal-title":"Stem Cells"},{"key":"8751_CR31","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/s43018-024-00838-6","volume":"5","author":"R Romero","year":"2024","unstructured":"Romero R, Chu T, Gonz\u00e1lez Robles TJ, Smith P, Xie Y, Kaur H, Yoder S, Zhao H, Mao C, Kang W, et al. The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. Nat Cancer. 2024;5:1641\u201359.","journal-title":"Nat Cancer"},{"key":"8751_CR32","doi-asserted-by":"crossref","first-page":"110595","DOI":"10.1016\/j.celrep.2022.110595","volume":"39","author":"H Han","year":"2022","unstructured":"Han H, Wang Y, Curto J, Gurrapu S, Laudato S, Rumandla A, Chakraborty G, Wang X, Chen H, Jiang Y, et al. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Rep. 2022;39:110595.","journal-title":"Cell Rep"},{"key":"8751_CR33","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.7150\/ijbs.120532","volume":"22","author":"\u00c1SA Carreira","year":"2026","unstructured":"Carreira \u00c1SA, Ciuffreda M, Thongon N, Haughey CM, Pickard A, Eddie SL, Steele RE, Cerri E, Belli R, Peroni D, et al. Nicotinamide N-Methyl Transferase (NNMT) Sustains Innate Sensitivity to NAMPT Inhibition in YAP-dependent Stem-like\/Mesenchymal Prostate Cancer. Int J Biol Sci. 2026;22:1126\u201341.","journal-title":"Int J Biol Sci"},{"key":"8751_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41419-025-08342-0","volume":"17","author":"F Sun","year":"2025","unstructured":"Sun F, Qu Y, Mei S, Zhang L, Shao X, Wang X, Liu S, Wang M, Liu W, Yang M, et al. CAMK1D activates AMPK\/PINK1\/Parkin-dependent mitophagy to promote enzalutamide resistance in prostate cancer. Cell Death Dis. 2025;17:113.","journal-title":"Cell Death Dis"},{"key":"8751_CR35","first-page":"113","volume":"1","author":"CP Tran","year":"2002","unstructured":"Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res. 2002;1:113\u201321.","journal-title":"Mol Cancer Res"},{"key":"8751_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s12253-016-0169-z","volume":"23","author":"E Kalantari","year":"2017","unstructured":"Kalantari E, Asgari M, Nikpanah S, Salarieh N, Asadi Lari MH, Madjd Z. Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas. Pathol Oncol Res. 2017;23:793\u2013802.","journal-title":"Pathol Oncol Res"},{"key":"8751_CR37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.canlet.2018.05.014","volume":"430","author":"R Kanwal","year":"2018","unstructured":"Kanwal R, Shukla S, Walker E, Gupta S. Acquisition of tumorigenic potential and therapeutic resistance in CD133\u2009+\u2009subpopulation of prostate cancer cells exhibiting stem-cell like characteristics. Cancer Lett. 2018;430:25\u201333.","journal-title":"Cancer Lett"},{"key":"8751_CR38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1541-7786.MCR-12-0551","volume":"11","author":"YC Lee","year":"2013","unstructured":"Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, et al. Targeting constitutively activated \u03b21 integrins inhibits prostate cancer metastasis. Mol Cancer Res. 2013;11:405\u201317.","journal-title":"Mol Cancer Res"},{"key":"8751_CR39","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1038\/bjc.2013.691","volume":"109","author":"FM Frame","year":"2013","unstructured":"Frame FM, Pellacani D, Collins AT, Simms MS, Mann VM, Jones GD, Meuth M, Bristow RG, Maitland NJ. HDAC inhibitor confers radiosensitivity to prostate stem-like cells. Br J Cancer. 2013;109:3023\u201333.","journal-title":"Br J Cancer"},{"key":"8751_CR40","first-page":"135","volume":"2","author":"M Trerotola","year":"2010","unstructured":"Trerotola M, Rathore S, Goel HL, Li J, Alberti S, Piantelli M, Adams D, Jiang Z, Languino LR. CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am J Transl Res. 2010;2:135\u201344.","journal-title":"Am J Transl Res"},{"key":"8751_CR41","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/s41388-018-0575-7","volume":"38","author":"CC Weng","year":"2019","unstructured":"Weng CC, Ding PY, Liu YH, Hawse JR, Subramaniam M, Wu CC, Lin YC, Chen CY, Hung WC, Cheng KH. Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis. Oncogene. 2019;38:2005\u201319.","journal-title":"Oncogene"},{"key":"8751_CR42","doi-asserted-by":"crossref","unstructured":"Verma S, Shankar E, Kalayci FNC, Mukunda A, Alassfar M, Singh V, Chan ER, MacLennan GT, Gupta S. Androgen deprivation induces transcriptional reprogramming in prostate cancer cells to develop stem cell-like characteristics. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21249568"},{"key":"8751_CR43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/labinvest.2009.127","volume":"90","author":"T Li","year":"2010","unstructured":"Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, Stass SA, Jiang F. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients\u2019 outcome. Lab Invest. 2010;90:234\u201344.","journal-title":"Lab Invest"},{"key":"8751_CR44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355:84\u20138.","journal-title":"Science"},{"key":"8751_CR45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.32471\/exp-oncology.2312-8852.vol-42-no-2.14673","volume":"42","author":"TV Zadvornyi","year":"2020","unstructured":"Zadvornyi TV, Lukianova NY, Borikun TV, Vitruk YV, Stakhovsky EO, Chekhun VF. NANOG as prognostic factor of prostate cancer course. Exp Oncol. 2020;42:94\u2013100.","journal-title":"Exp Oncol"},{"key":"8751_CR46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12967-023-04834-9","volume":"22","author":"E Zhang","year":"2024","unstructured":"Zhang E, Chen Z, Liu W, Lin L, Wu L, Guan J, Wang J, Kong C, Bi J, Zhang M. NCAPG2 promotes prostate cancer malignancy and stemness via STAT3\/c-MYC signaling. J Transl Med. 2024;22:12.","journal-title":"J Transl Med"},{"key":"8751_CR47","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.pdpdt.2021.102452","volume":"35","author":"S Yamamoto","year":"2021","unstructured":"Yamamoto S, Fukuhara H, Seki H, Kawada C, Nakayama T, Karashima T, Ogura SI, Inoue K. Predictors of therapeutic efficacy of 5-aminolevulinic acid-based photodynamic therapy in human prostate cancer. Photodiagnosis Photodyn Ther. 2021;35:102452.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"8751_CR48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/1541-7786.MCR-16-0270-T","volume":"15","author":"NG Sabnis","year":"2017","unstructured":"Sabnis NG, Miller A, Titus MA, Huss WJ. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells. Mol Cancer Res. 2017;15:128\u201340.","journal-title":"Mol Cancer Res"},{"key":"8751_CR49","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/pros.22867","volume":"74","author":"E Guzel","year":"2014","unstructured":"Guzel E, Karatas OF, Duz MB, Solak M, Ittmann M, Ozen M. Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer. Prostate. 2014;74:1498\u2013505.","journal-title":"Prostate"},{"key":"8751_CR50","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/CAD.0000000000000659","volume":"29","author":"S Qiu","year":"2018","unstructured":"Qiu S, Deng L, Bao Y, Jin K, Tu X, Li J, Liao X, Liu Z, Yang L, Wei Q. Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition. Anticancer Drugs. 2018;29:871\u20139.","journal-title":"Anticancer Drugs"},{"key":"8751_CR51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5114\/pjp.2014.48190","volume":"65","author":"K Korski","year":"2014","unstructured":"Korski K, Malicka-Durczak A, Br\u0119borowicz J. Expression of stem cell marker CD44 in prostate cancer biopsies predicts cancer grade in radical prostatectomy specimens. Pol J Pathol. 2014;65:291\u20135.","journal-title":"Pol J Pathol"},{"key":"8751_CR52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/pros.21217","volume":"71","author":"AV Ugolkov","year":"2011","unstructured":"Ugolkov AV, Eisengart LJ, Luan C, Yang XJ. Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate. 2011;71:18\u201325.","journal-title":"Prostate"},{"key":"8751_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10585-011-9423-7","volume":"29","author":"W Xiao","year":"2012","unstructured":"Xiao W, Graham PH, Power CA, Hao J, Kearsley JH, Li Y. CD44 is a biomarker associated with human prostate cancer radiation sensitivity. Clin Exp Metastasis. 2012;29:1\u20139.","journal-title":"Clin Exp Metastasis"},{"key":"8751_CR54","doi-asserted-by":"crossref","first-page":"472","DOI":"10.7150\/ijbs.5855","volume":"9","author":"L Wang","year":"2013","unstructured":"Wang L, Huang X, Zheng X, Wang X, Li S, Zhang L, Yang Z, Xia Z. Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemoradiotherapy. Int J Biol Sci. 2013;9:472\u20139.","journal-title":"Int J Biol Sci"},{"key":"8751_CR55","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/cdd.2014.97","volume":"22","author":"L Kyjacova","year":"2015","unstructured":"Kyjacova L, Hubackova S, Krejcikova K, Strauss R, Hanzlikova H, Dzijak R, Imrichova T, Simova J, Reinis M, Bartek J, Hodny Z. Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent cells. Cell Death Differ. 2015;22:898\u2013911.","journal-title":"Cell Death Differ"},{"key":"8751_CR56","doi-asserted-by":"crossref","first-page":"e2437871","DOI":"10.1001\/jamanetworkopen.2024.37871","volume":"7","author":"A Goldkorn","year":"2024","unstructured":"Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski JK, Ingles S, Triche TJ, MacVicar GR, Vaena DA, et al. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Netw Open. 2024;7:e2437871.","journal-title":"JAMA Netw Open"},{"key":"8751_CR57","doi-asserted-by":"crossref","unstructured":"Zavridou M, Strati A, Bournakis E, Smilkou S, Tserpeli V, Lianidou E. Prognostic significance of gene expression and dna methylation markers in circulating tumor cells and paired plasma derived exosomes in metastatic castration resistant prostate cancer. Cancers (Basel). 2021;13.","DOI":"10.3390\/cancers13040780"},{"key":"8751_CR58","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clgc.2014.08.014","volume":"13","author":"SK Pal","year":"2015","unstructured":"Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, Torres A, Hernandez S, Lau C, Agarwal N, et al. Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. Clin Genitourin Cancer. 2015;13:130\u20136.","journal-title":"Clin Genitourin Cancer"},{"key":"8751_CR59","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1158\/1078-0432.CCR-06-0422","volume":"12","author":"N Mehra","year":"2006","unstructured":"Mehra N, Penning M, Maas J, Beerepoot LV, van Daal N, van Gils CH, Giles RH, Voest EE. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res. 2006;12:4859\u201366.","journal-title":"Clin Cancer Res"},{"key":"8751_CR60","doi-asserted-by":"crossref","first-page":"e52993","DOI":"10.1371\/journal.pone.0052993","volume":"8","author":"HR Siddique","year":"2013","unstructured":"Siddique HR, Parray A, Zhong W, Karnes RJ, Bergstralh EJ, Koochekpour S, Rhim JS, Konety BR, Saleem M. BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer. PLoS ONE. 2013;8:e52993.","journal-title":"PLoS ONE"},{"key":"8751_CR61","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/cr.2009.43","volume":"19","author":"I Bisson","year":"2009","unstructured":"Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 2009;19:683\u201397.","journal-title":"Cell Res"},{"key":"8751_CR62","doi-asserted-by":"crossref","first-page":"189186","DOI":"10.1016\/j.bbcan.2024.189186","volume":"1879","author":"Y Hou","year":"2024","unstructured":"Hou Y, Zhao Z, Li P, Cao Y, Zhang Y, Guo C, Nie X, Hou J. Combination therapies with Wnt signaling inhibition: A better choice for prostate cancer treatment. Biochim Biophys Acta Rev Cancer. 2024;1879:189186.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8751_CR63","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41391-024-00869-1","volume":"28","author":"A Broderick","year":"2025","unstructured":"Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, et al. Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2025;28:419\u201326.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"8751_CR64","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/0008-5472.CAN-21-1807","volume":"82","author":"F Ma","year":"2022","unstructured":"Ma F, Arai S, Wang K, Calagua C, Yuan AR, Poluben L, Gu Z, Russo JW, Einstein DJ, Ye H, et al. Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer. Cancer Res. 2022;82:1518\u201333.","journal-title":"Cancer Res"},{"key":"8751_CR65","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1541-7786.MCR-24-0395","volume":"22","author":"SH Choi","year":"2024","unstructured":"Choi SH, Pan E, Elliott A, Beltran H, Panian J, Jamieson C, Bagrodia A, Rose B, Herchenhorn D, Heath E, et al. Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer. Mol Cancer Res. 2024;22:920\u201331.","journal-title":"Mol Cancer Res"},{"key":"8751_CR66","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2019.05.032","volume":"77","author":"P Isaacsson Velho","year":"2020","unstructured":"Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, Shaukat F, Carducci MA, Denmeade SR, Paller CJ, et al. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. Eur Urol. 2020;77:14\u201321.","journal-title":"Eur Urol"},{"key":"8751_CR67","doi-asserted-by":"crossref","first-page":"606","DOI":"10.18632\/oncotarget.28758","volume":"16","author":"A Deacon","year":"2025","unstructured":"Deacon A, Gustafson A, Makovec A, Boytim E, von Dohlen G, Moline D, Kairies E, Kellen S, Ishani K, Ludwig ML, et al. Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer. Oncotarget. 2025;16:606\u201320.","journal-title":"Oncotarget"},{"key":"8751_CR68","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biopha.2018.01.086","volume":"99","author":"XL Song","year":"2018","unstructured":"Song XL, Huang B, Zhou BW, Wang C, Liao ZW, Yu Y, Zhao SC. miR-1301-3p promotes prostate cancer stem cell expansion by targeting SFRP1 and GSK3\u03b2. Biomed Pharmacother. 2018;99:369\u201374.","journal-title":"Biomed Pharmacother"},{"key":"8751_CR69","first-page":"4361","volume":"12","author":"H Du","year":"2019","unstructured":"Du H, Wang X, Dong R, Hu D, Xiong Y. miR-601 inhibits proliferation, migration and invasion of prostate cancer stem cells by targeting KRT5 to inactivate the Wnt signaling pathway. Int J Clin Exp Pathol. 2019;12:4361\u201379.","journal-title":"Int J Clin Exp Pathol"},{"key":"8751_CR70","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/carcin\/bgs371","volume":"34","author":"IS Hsieh","year":"2013","unstructured":"Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ, Lee KH, Yeh SD, Hong TM, Chen YL. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt\/beta-catenin signaling pathway. Carcinogenesis. 2013;34:530\u20138.","journal-title":"Carcinogenesis"},{"key":"8751_CR71","doi-asserted-by":"crossref","first-page":"e70887","DOI":"10.1002\/cam4.70887","volume":"14","author":"H Guan","year":"2025","unstructured":"Guan H, Hu Q, Wan L, Wang C, Xue Y, Feng N, Zhao C, Chen M, You Z. LINC00908 Inactivates Wnt\/\u03b2-Catenin Signaling Pathway to Inhibit Prostate Cancer Cell Stemness via Upregulating GSK3B and FBXW2. Cancer Med. 2025;14:e70887.","journal-title":"Cancer Med"},{"key":"8751_CR72","doi-asserted-by":"crossref","unstructured":"Liu J, Niraj M, Wang H, Zhang W, Wang R, Kadier A, Li W, Yao X. Down-regulation of lncRNA MBNL1-AS1 promotes tumor stem cell-like characteristics and prostate cancer progression through miR-221-3p\/CDKN1B\/C-myc axis. Cancers (Basel). 2022;14.","DOI":"10.3390\/cancers14235783"},{"key":"8751_CR73","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s11658-025-00814-7","volume":"30","author":"K Chen","year":"2025","unstructured":"Chen K, Pan X, Zhang S, Xu M, Chen X, Pei F, Wu M, Meng F, Sun B, Zhang M, Luo Y. Circular RNA circSLC39A10 promotes prostate cancer progression by activating Wnt signaling via the miR-936\/PROX1\/\u03b2-catenin axis. Cell Mol Biol Lett. 2025;30:126.","journal-title":"Cell Mol Biol Lett"},{"key":"8751_CR74","doi-asserted-by":"crossref","unstructured":"Li S, Yu C, Zhang Y, Liu J, Jia Y, Sun F, Zhang P, Li J, Guo L, Xiao H, et al. Circular RNA cir-ITCH is a potential therapeutic target for the treatment of castration-resistant prostate cancer. Biomed Res Int. 2020;2020:7586521.","DOI":"10.1155\/2020\/7586521"},{"key":"8751_CR75","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.18632\/oncotarget.3469","volume":"6","author":"F Li","year":"2015","unstructured":"Li F, Zhang L, Li W, Deng J, Zheng J, An M, Lu J, Zhou Y. Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt\/\u03b2-catenin pathway. Oncotarget. 2015;6:6001\u201313.","journal-title":"Oncotarget"},{"key":"8751_CR76","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.gene.2016.08.030","volume":"593","author":"P Garc\u00eda-Tobilla","year":"2016","unstructured":"Garc\u00eda-Tobilla P, Sol\u00f3rzano SR, Salido-Guadarrama I, Gonz\u00e1lez-Covarrubias V, Morales-Montor G, D\u00edaz-Ota\u00f1ez CE. Rodr\u00edguez-Dorantes M: SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms. Gene. 2016;593:292\u2013301.","journal-title":"Gene"},{"key":"8751_CR77","doi-asserted-by":"crossref","first-page":"E3395","DOI":"10.1073\/pnas.1217982109","volume":"109","author":"Y Zong","year":"2012","unstructured":"Zong Y, Huang J, Sankarasharma D, Morikawa T, Fukayama M, Epstein JI, Chada KK, Witte ON. Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc Natl Acad Sci U S A. 2012;109:E3395\u20133404.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8751_CR78","doi-asserted-by":"publisher","first-page":"6560","DOI":"10.1038\/sj.onc.1210472","volume":"26","author":"Q Wang","year":"2007","unstructured":"Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, Hubank MJ, Ahmed A, Masters JR. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene. 2007;26:6560\u20135.","journal-title":"Oncogene"},{"key":"8751_CR79","doi-asserted-by":"crossref","unstructured":"Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, Thoren KL, Abida W, Sfanos KS, De Marzo AM, et al. Dickkopf-1 can lead to immune evasion in metastatic castration-resistant prostate cancer. JCO Precis Oncol. 2020;4.","DOI":"10.1200\/PO.20.00097"},{"key":"8751_CR80","doi-asserted-by":"crossref","first-page":"25562","DOI":"10.1074\/jbc.M201196200","volume":"277","author":"D Wolf","year":"2002","unstructured":"Wolf D, Rodova M, Miska EA, Calvet JP, Kouzarides T. Acetylation of beta-catenin by CREB-binding protein (CBP). J Biol Chem. 2002;277:25562\u20137.","journal-title":"J Biol Chem"},{"key":"8751_CR81","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1038\/s41388-020-1214-7","volume":"39","author":"Y He","year":"2020","unstructured":"He Y, Mi J, Olson A, Aldahl J, Hooker E, Yu EJ, Le V, Lee DH, Kim WK, Robins DM, et al. Androgen receptor with short polyglutamine tract preferably enhances Wnt\/\u03b2-catenin-mediated prostatic tumorigenesis. Oncogene. 2020;39:3276\u201391.","journal-title":"Oncogene"},{"key":"8751_CR82","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/onc.2015.117","volume":"35","author":"SH Lee","year":"2016","unstructured":"Lee SH, Luong R, Johnson DT, Cunha GR, Rivina L, Gonzalgo ML, Sun Z. Androgen signaling is a confounding factor for \u03b2-catenin-mediated prostate tumorigenesis. Oncogene. 2016;35:702\u201314.","journal-title":"Oncogene"},{"key":"8751_CR83","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/s41388-018-0497-4","volume":"38","author":"VC Pai","year":"2019","unstructured":"Pai VC, Hsu CC, Chan TS, Liao WY, Chuu CP, Chen WY, Li CR, Lin CY, Huang SP, Chen LT, Tsai KK. ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-\u03b2-catenin signaling. Oncogene. 2019;38:1340\u201353.","journal-title":"Oncogene"},{"key":"8751_CR84","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41419-024-06621-w","volume":"15","author":"X Zhang","year":"2024","unstructured":"Zhang X, Li H, Wang Y, Zhao H, Wang Z, Chan FL. Nuclear receptor NURR1 functions to promote stemness and epithelial-mesenchymal transition in prostate cancer via its targeting of Wnt\/\u03b2-catenin signaling pathway. Cell Death Dis. 2024;15:234.","journal-title":"Cell Death Dis"},{"key":"8751_CR85","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22:138.","journal-title":"Mol Cancer"},{"key":"8751_CR86","doi-asserted-by":"crossref","unstructured":"Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT Signaling. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21124507"},{"key":"8751_CR87","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15:222\u201334.","journal-title":"Nat Rev Urol"},{"key":"8751_CR88","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/path.4977","volume":"243","author":"MT Jefferies","year":"2017","unstructured":"Jefferies MT, Cox AC, Shorning BY, Meniel V, Griffiths D, Kynaston HG, Smalley MJ, Clarke AR. PTEN loss and activation of K-RAS and \u03b2-catenin cooperate to accelerate prostate tumourigenesis. J Pathol. 2017;243:442\u201356.","journal-title":"J Pathol"},{"key":"8751_CR89","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/2159-8290.CD-17-0867","volume":"8","author":"HB Pearson","year":"2018","unstructured":"Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, Rebello RJ, Macpherson AA, Koushyar S, Furic L, et al. Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth. Cancer Discov. 2018;8:764\u201379.","journal-title":"Cancer Discov"},{"key":"8751_CR90","doi-asserted-by":"crossref","first-page":"368","DOI":"10.18632\/genesandcancer.128","volume":"7","author":"A Persad","year":"2016","unstructured":"Persad A, Venkateswaran G, Hao L, Garcia ME, Yoon J, Sidhu J, Persad S. Active \u03b2-catenin is regulated by the PTEN\/PI3 kinase pathway: a role for protein phosphatase PP2A. Genes Cancer. 2016;7:368\u201382.","journal-title":"Genes Cancer"},{"key":"8751_CR91","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cellsig.2015.01.001","volume":"27","author":"H Liu","year":"2015","unstructured":"Liu H, Yin J, Wang H, Jiang G, Deng M, Zhang G, Bu X, Cai S, Du J, He Z. FOXO3a modulates WNT\/\u03b2-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Cell Signal. 2015;27:510\u20138.","journal-title":"Cell Signal"},{"key":"8751_CR92","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/0008-5472.CAN-15-1868","volume":"76","author":"B Bilir","year":"2016","unstructured":"Bilir B, Osunkoya AO, Wiles WGt, Sannigrahi S, Lefebvre V, Metzger D, Spyropoulos DD, Martin WD, Moreno CS. SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation. Cancer Res. 2016;76:1112\u201321.","journal-title":"Cancer Res"},{"key":"8751_CR93","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","volume":"10","author":"BD Manning","year":"2002","unstructured":"Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway. Mol Cell. 2002;10:151\u201362.","journal-title":"Mol Cell"},{"key":"8751_CR94","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/jcb.24850","volume":"115","author":"W Lu","year":"2014","unstructured":"Lu W, Li Y. Salinomycin suppresses LRP6 expression and inhibits both Wnt\/\u03b2-catenin and mTORC1 signaling in breast and prostate cancer cells. J Cell Biochem. 2014;115:1799\u2013807.","journal-title":"J Cell Biochem"},{"key":"8751_CR95","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1101\/gad.1909210","volume":"24","author":"B Zhao","year":"2010","unstructured":"Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010;24:862\u201374.","journal-title":"Genes Dev"},{"key":"8751_CR96","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.semcancer.2021.07.006","volume":"85","author":"FL Li","year":"2022","unstructured":"Li FL, Guan KL. The two sides of Hippo pathway in cancer. Semin Cancer Biol. 2022;85:33\u201342.","journal-title":"Semin Cancer Biol"},{"key":"8751_CR97","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1021\/acs.biochem.5b01014","volume":"54","author":"K Zhang","year":"2015","unstructured":"Zhang K, Qi HX, Hu ZM, Chang YN, Shi ZM, Han XH, Han YW, Zhang RX, Zhang Z, Chen T, Hong W. YAP and TAZ Take Center Stage in Cancer. Biochemistry. 2015;54:6555\u201366.","journal-title":"Biochemistry"},{"key":"8751_CR98","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cell.2014.06.013","volume":"158","author":"L Azzolin","year":"2014","unstructured":"Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, et al. YAP\/TAZ incorporation in the \u03b2-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158:157\u201370.","journal-title":"Cell"},{"key":"8751_CR99","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.cell.2012.11.027","volume":"151","author":"L Azzolin","year":"2012","unstructured":"Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, Cordenonsi M, Piccolo S. Role of TAZ as mediator of Wnt signaling. Cell. 2012;151:1443\u201356.","journal-title":"Cell"},{"key":"8751_CR100","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.bbrc.2017.03.158","volume":"486","author":"WI Seo","year":"2017","unstructured":"Seo WI, Park S, Gwak J, Ju BG, Chung JI, Kang PM, Oh S. Wnt signaling promotes androgen-independent prostate cancer cell proliferation through up-regulation of the hippo pathway effector YAP. Biochem Biophys Res Commun. 2017;486:1034\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"8751_CR101","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1158\/0008-5472.CAN-22-3003","volume":"83","author":"K Wang","year":"2023","unstructured":"Wang K, Ma F, Arai S, Wang Y, Varkaris A, Poluben L, Voznesensky O, Xie F, Zhang X, Yuan X, Balk SP. WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth. Cancer Res. 2023;83:1016\u201330.","journal-title":"Cancer Res"},{"key":"8751_CR102","doi-asserted-by":"publisher","first-page":"16577","DOI":"10.1038\/s41598-017-16441-y","volume":"7","author":"Y Xie","year":"2017","unstructured":"Xie Y, Sun Q, Nurkesh AA, Lu J, Kauanova S, Feng J, Tursynkhan D, Yang Q, Kassymbek A, Karibayev M, et al. Dysregulation of YAP by ARF Stimulated with Tea-derived Carbon Nanodots. Sci Rep. 2017;7:16577.","journal-title":"Sci Rep"},{"key":"8751_CR103","doi-asserted-by":"crossref","unstructured":"Lai HW, Kasai M, Yamamoto S, Fukuhara H, Karashima T, Kurabayashi A, Furihata M, Hanazaki K, Inoue K, Ogura SI. Metabolic shift towards oxidative phosphorylation reduces cell-density-induced cancer-stem-cell-like characteristics in prostate cancer in vitro. Biol Open. 2023;12.","DOI":"10.1242\/bio.059615"},{"key":"8751_CR104","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41585-020-0288-x","volume":"17","author":"DA Bader","year":"2020","unstructured":"Bader DA, McGuire SE. Tumour metabolism and its unique properties in prostate adenocarcinoma. Nat Rev Urol. 2020;17:214\u201331.","journal-title":"Nat Rev Urol"},{"key":"8751_CR105","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.7150\/thno.58655","volume":"11","author":"A Mukha","year":"2021","unstructured":"Mukha A, Kahya U, Linge A, Chen O, L\u00f6ck S, Lukiyanchuk V, Richter S, Alves TC, Peitzsch M, Telychko V, et al. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics. 2021;11:7844\u201368.","journal-title":"Theranostics"},{"key":"8751_CR106","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature07823","volume":"458","author":"P Gao","year":"2009","unstructured":"Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT. Dang CV: c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762\u20135.","journal-title":"Nature"},{"key":"8751_CR107","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36:1461\u201373.","journal-title":"Oncogene"},{"key":"8751_CR108","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/s41388-021-02157-x","volume":"41","author":"L de Wet","year":"2022","unstructured":"de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, Vellky JE, Brown R, Conger K, Paner GP, et al. SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene. 2022;41:1190\u2013202.","journal-title":"Oncogene"},{"key":"8751_CR109","doi-asserted-by":"crossref","unstructured":"Yang X, Guo C, Lu Y, Zhou R, Liu Z, Yang Z, Xu S, Li W. Lactylation of \u03b2-catenin promotes non-small cell lung cancer by inhibiting ferroptosis through TCF4-mediated GPX4 transcription. J Transl Med. 2026;24.","DOI":"10.1186\/s12967-026-08247-2"},{"key":"8751_CR110","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1158\/1078-0432.CCR-23-1441","volume":"29","author":"K Chaudagar","year":"2023","unstructured":"Chaudagar K, Hieromnimon HM, Kelley A, Labadie B, Shafran J, Rameshbabu S, Drovetsky C, Bynoe K, Solanki A, Markiewicz E, et al. Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN\/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis. Clin Cancer Res. 2023;29:4930\u201340.","journal-title":"Clin Cancer Res"},{"key":"8751_CR111","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/labinvest.2008.97","volume":"88","author":"M Fiorentino","year":"2008","unstructured":"Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, et al. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest. 2008;88:1340\u20138.","journal-title":"Lab Invest"},{"key":"8751_CR112","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12967-025-06322-8","volume":"23","author":"Y Guo","year":"2025","unstructured":"Guo Y, Zhang Z, Dong L, Shi X, Li X, Luo M, Fu Y, Gao Y. Wnt5a augments intracellular free cholesterol levels and promotes castration resistance in prostate cancer. J Transl Med. 2025;23:347.","journal-title":"J Transl Med"},{"key":"8751_CR113","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1158\/1541-7786.MCR-17-0665","volume":"16","author":"HJ Lee","year":"2018","unstructured":"Lee HJ, Li J, Vickman RE, Li J, Liu R, Durkes AC, Elzey BD, Yue S, Liu X, Ratliff TL, Cheng JX. Cholesterol Esterification Inhibition Suppresses Prostate Cancer Metastasis by Impairing the Wnt\/\u03b2-catenin Pathway. Mol Cancer Res. 2018;16:974\u201385.","journal-title":"Mol Cancer Res"},{"key":"8751_CR114","doi-asserted-by":"crossref","first-page":"1617200","DOI":"10.3389\/fcell.2025.1617200","volume":"13","author":"H Chen","year":"2025","unstructured":"Chen H, Li Z, Yue Y, Zhu X, Wang J, Chen Y, Wang Y, Luo Z, Liu H. CAF-mediated regulation of prostate cancer stem cell stemness via the Wnt\/\u03b2-catenin and SDF-1\/CXCR4 pathways in castration-resistant prostate cancer. Front Cell Dev Biol. 2025;13:1617200.","journal-title":"Front Cell Dev Biol"},{"key":"8751_CR115","doi-asserted-by":"crossref","first-page":"1096923","DOI":"10.3389\/fcell.2023.1096923","volume":"11","author":"A Losada-Garc\u00eda","year":"2023","unstructured":"Losada-Garc\u00eda A, Salido-Guadarrama I, Cortes-Ramirez SA, Cruz-Burgos M, Morales-Pacheco M, Vazquez-Santillan K, Rodriguez-Martinez G, Gonz\u00e1lez-Ram\u00edrez I, Gonzalez-Covarrubias V, Perez-Plascencia C. Rodr\u00edguez-Dorantes M: SFRP1 induces a stem cell phenotype in prostate cancer cells. Front Cell Dev Biol. 2023;11:1096923.","journal-title":"Front Cell Dev Biol"},{"key":"8751_CR116","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41419-020-2435-y","volume":"11","author":"R Huang","year":"2020","unstructured":"Huang R, Wang S, Wang N, Zheng Y, Zhou J, Yang B, Wang X, Zhang J, Guo L, Wang S, et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating \u03b2-catenin\/STAT3 signaling. Cell Death Dis. 2020;11:234.","journal-title":"Cell Death Dis"},{"key":"8751_CR117","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704\u201315.","journal-title":"Cell"},{"key":"8751_CR118","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1136\/gutjnl-2014-307900","volume":"65","author":"J Qi","year":"2016","unstructured":"Qi J, Yu Y, Akilli \u00d6zt\u00fcrk \u00d6, Holland JD, Besser D, Fritzmann J, Wulf-Goldenberg A, Eckert K, Fichtner I, Birchmeier W. New Wnt\/\u03b2-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals. Gut. 2016;65:1690\u2013701.","journal-title":"Gut"},{"key":"8751_CR119","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1073\/pnas.0908133107","volume":"107","author":"D Xie","year":"2010","unstructured":"Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, Long M, Kabbani W, Yu L, Zhang H, et al. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A. 2010;107:2485\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8751_CR120","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1078-0432.CCR-15-0190","volume":"22","author":"EJ Yun","year":"2016","unstructured":"Yun EJ, Zhou J, Lin CJ, Hernandez E, Fazli L, Gleave M, Hsieh JT. Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2016;22:670\u20139.","journal-title":"Clin Cancer Res"},{"key":"8751_CR121","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/0008-5472.CAN-13-1313","volume":"74","author":"X Ju","year":"2014","unstructured":"Ju X, Casimiro MC, Gormley M, Meng H, Jiao X, Katiyar S, Crosariol M, Chen K, Wang M, Quong AA, et al. Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint. Cancer Res. 2014;74:508\u201319.","journal-title":"Cancer Res"},{"key":"8751_CR122","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/0008-5472.CAN-14-1924","volume":"75","author":"M Cojoc","year":"2015","unstructured":"Cojoc M, Peitzsch C, Kurth I, Trautmann F, Kunz-Schughart LA, Telegeev GD, Stakhovsky EA, Walker JR, Simin K, Lyle S, et al. Aldehyde Dehydrogenase Is Regulated by \u03b2-Catenin\/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. Cancer Res. 2015;75:1482\u201394.","journal-title":"Cancer Res"},{"key":"8751_CR123","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/pros.22775","volume":"74","author":"J Ni","year":"2014","unstructured":"Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, Shigdar S, Delprado WJ, Graham PH, Bucci J, et al. CD44 variant 6 is associated with prostate cancer metastasis and chemo-\/radioresistance. Prostate. 2014;74:602\u201317.","journal-title":"Prostate"},{"key":"8751_CR124","doi-asserted-by":"crossref","first-page":"e2411321121","DOI":"10.1073\/pnas.2411321121","volume":"121","author":"Y Yang","year":"2024","unstructured":"Yang Y, Zhang X, Cai D, Zheng X, Zhao X, Zou JX, Zhang J, Borowsky AD, Dall\u2019Era MA, Corey E, et al. Functional inversion of circadian regulator REV-ERB\u03b1 leads to tumorigenic gene reprogramming. Proc Natl Acad Sci U S A. 2024;121:e2411321121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8751_CR125","doi-asserted-by":"crossref","unstructured":"Yang Y, Zhang X, Venkadakrishnan VB, Zou H, Zheng X, Guo S, Chen CZ, Borowsky AD, Corey E, Evans RM, et al. Targeting Wnt\/\u03b2-catenin and circadian regulator restores PRC2\/EZH2-controlled chromatin bivalency and suppresses cell state diversity. J Clin Invest. 2026:136.","DOI":"10.1172\/JCI200260"},{"key":"8751_CR126","doi-asserted-by":"crossref","first-page":"656981","DOI":"10.3389\/fcell.2021.656981","volume":"9","author":"Q Li","year":"2021","unstructured":"Li Q, Xia D, Wang Z, Liu B, Zhang J, Peng P, Tang Q, Dong J, Guo J, Kuang D, et al. Circadian Rhythm Gene PER3 Negatively Regulates Stemness of Prostate Cancer Stem Cells via WNT\/\u03b2-Catenin Signaling in Tumor Microenvironment. Front Cell Dev Biol. 2021;9:656981.","journal-title":"Front Cell Dev Biol"},{"key":"8751_CR127","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1093\/nar\/gkae206","volume":"52","author":"N Lepp\u00e4nen","year":"2024","unstructured":"Lepp\u00e4nen N, Kaljunen H, Takala E, Kaarij\u00e4rvi R, M\u00e4kinen PI, Yl\u00e4-Herttuala S, Paatero I, Paakinaho V, Ketola K. SIX2 promotes cell plasticity via Wnt\/\u03b2-catenin signalling in androgen receptor independent prostate cancer. Nucleic Acids Res. 2024;52:5610\u201323.","journal-title":"Nucleic Acids Res"},{"key":"8751_CR128","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1158\/1541-7786.MCR-14-0503","volume":"13","author":"J Liang","year":"2015","unstructured":"Liang J, Li Y, Daniels G, Sfanos K, De Marzo A, Wei J, Li X, Chen W, Wang J, Zhong X, et al. LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a. Mol Cancer Res. 2015;13:681\u20138.","journal-title":"Mol Cancer Res"},{"key":"8751_CR129","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm.2284","volume":"17","author":"C Liu","year":"2011","unstructured":"Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17:211\u20135.","journal-title":"Nat Med"},{"key":"8751_CR130","first-page":"472","volume":"34","author":"Y Cui","year":"2019","unstructured":"Cui Y, Yang Y, Ren L, Yang J, Wang B, Xing T, Chen H, Chen M. miR-15a-3p Suppresses Prostate Cancer Cell Proliferation and Invasion by Targeting SLC39A7 Via Downregulating Wnt\/\u03b2-Catenin Signaling Pathway. Cancer Biother Radiopharm. 2019;34:472\u20139.","journal-title":"Cancer Biother Radiopharm"},{"key":"8751_CR131","doi-asserted-by":"crossref","first-page":"152537","DOI":"10.1016\/j.prp.2019.152537","volume":"215","author":"Y Han","year":"2019","unstructured":"Han Y, Hu H, Zhou J. Knockdown of LncRNA SNHG7 inhibited epithelial-mesenchymal transition in prostate cancer though miR-324-3p\/WNT2B axis in vitro. Pathol Res Pract. 2019;215:152537.","journal-title":"Pathol Res Pract"},{"key":"8751_CR132","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1186\/s12935-020-01665-2","volume":"20","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Li Y. Long non-coding RNA NORAD contributes to the proliferation, invasion and EMT progression of prostate cancer via the miR-30a-5p\/RAB11A\/WNT\/\u03b2-catenin pathway. Cancer Cell Int. 2020;20:571.","journal-title":"Cancer Cell Int"},{"key":"8751_CR133","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, Sch\u00f6pfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578\u201383.","journal-title":"Hum Pathol"},{"key":"8751_CR134","doi-asserted-by":"crossref","unstructured":"Castell\u00f3n EA, Indo S, Contreras HR. Cancer stemness\/epithelial-mesenchymal transition axis influences metastasis and castration resistance in prostate cancer: potential therapeutic target. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms232314917"},{"key":"8751_CR135","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/1541-7786.MCR-13-0332-T","volume":"11","author":"Y Jiang","year":"2013","unstructured":"Jiang Y, Dai J, Zhang H, Sottnik JL, Keller JM, Escott KJ, Sanganee HJ, Yao Z, McCauley LK, Keller ET. Activation of the Wnt pathway through AR79, a GSK3\u03b2 inhibitor, promotes prostate cancer growth in soft tissue and bone. Mol Cancer Res. 2013;11:1597\u2013610.","journal-title":"Mol Cancer Res"},{"key":"8751_CR136","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41417-022-00563-1","volume":"30","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang C, Chen S, Liu W, Liang J, He S, Hui J. Cancer-derived exosomal miR-375 targets DIP2C and promotes osteoblastic metastasis and prostate cancer progression by regulating the Wnt signaling pathway. Cancer Gene Ther. 2023;30:437\u201349.","journal-title":"Cancer Gene Ther"},{"key":"8751_CR137","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canlet.2017.05.029","volume":"402","author":"Q Li","year":"2017","unstructured":"Li Q, Ye L, Zhang X, Wang M, Lin C, Huang S, Guo W, Lai Y, Du H, Li J, et al. FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt\/\u03b2-catenin signaling. Cancer Lett. 2017;402:166\u201376.","journal-title":"Cancer Lett"},{"key":"8751_CR138","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/cam4.111","volume":"2","author":"SA Rabbani","year":"2013","unstructured":"Rabbani SA, Arakelian A, Farookhi R. LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Med. 2013;2:625\u201335.","journal-title":"Cancer Med"},{"key":"8751_CR139","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1158\/0008-5472.CAN-12-1343","volume":"73","author":"Y Zeng","year":"2013","unstructured":"Zeng Y, Wodzenski D, Gao D, Shiraishi T, Terada N, Li Y, Vander Griend DJ, Luo J, Kong C, Getzenberg RH, Kulkarni P. Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing. Cancer Res. 2013;73:4123\u201333.","journal-title":"Cancer Res"},{"key":"8751_CR140","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41419-023-05627-0","volume":"14","author":"S Zhang","year":"2023","unstructured":"Zhang S, Lv C, Niu Y, Li C, Li X, Shang Y, Zhang Y, Zhang Y, Zhang Y, Zeng Y. RBM3 suppresses stemness remodeling of prostate cancer in bone microenvironment by modulating N6-methyladenosine on CTNNB1 mRNA. Cell Death Dis. 2023;14:91.","journal-title":"Cell Death Dis"},{"key":"8751_CR141","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5114\/pjp.2025.150029","volume":"76","author":"S Ye","year":"2025","unstructured":"Ye S, Lin Q, Deng M, Huang S, Mao C, Zhang J, Zhan W, Chen G. Crosstalk between OPG\/RANKL\/RANK in bone marrow mesenchymal stem cells and Wnt\/b-catenin pathway in prostate cancer cells regulates bone metastasis of prostate cancer. Pol J Pathol. 2025;76:25\u201337.","journal-title":"Pol J Pathol"},{"key":"8751_CR142","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3892\/mmr.2013.1698","volume":"8","author":"F Jin","year":"2013","unstructured":"Jin F, Qu X, Fan Q, Wang L, Tang T, Hao Y, Dai K. Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling. Mol Med Rep. 2013;8:1486\u201392.","journal-title":"Mol Med Rep"},{"key":"8751_CR143","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/pros.23940","volume":"80","author":"M Gruber","year":"2020","unstructured":"Gruber M, Handle F, Culig Z. The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells. Prostate. 2020;80:267\u201373.","journal-title":"Prostate"},{"key":"8751_CR144","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/bjc.2011.530","volume":"106","author":"K Ketola","year":"2012","unstructured":"Ketola K, Hilvo M, Hy\u00f6tyl\u00e4inen T, Vuoristo A, Ruskeep\u00e4\u00e4 AL, Ore\u0161i\u010d M, Kallioniemi O, Iljin K. Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer. 2012;106:99\u2013106.","journal-title":"Br J Cancer"},{"key":"8751_CR145","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1158\/1535-7163.MCT-22-0216","volume":"21","author":"S Ning","year":"2022","unstructured":"Ning S, Liu C, Lou W, Yang JC, Lombard AP, D\u2019Abronzo LS, Batra N, Yu AM, Leslie AR, Sharifi M, et al. Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a\/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Mol Cancer Ther. 2022;21:1594\u2013607.","journal-title":"Mol Cancer Ther"},{"key":"8751_CR146","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/0008-5472.CAN-10-0244","volume":"70","author":"S Gupta","year":"2010","unstructured":"Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M, Kallioniemi O. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2010;70:6735\u201345.","journal-title":"Cancer Res"},{"key":"8751_CR147","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/jcb.23070","volume":"112","author":"S Thiele","year":"2011","unstructured":"Thiele S, Rauner M, Goettsch C, Rachner TD, Benad P, Fuessel S, Erdmann K, Hamann C, Baretton GB, Wirth MP, et al. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell Biochem. 2011;112:1593\u2013600.","journal-title":"J Cell Biochem"},{"key":"8751_CR148","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1038\/s41388-022-02255-4","volume":"41","author":"L Wang","year":"2022","unstructured":"Wang L, Wang J, Yin X, Guan X, Li Y, Xin C, Liu J. GIPC2 interacts with Fzd7 to promote prostate cancer metastasis by activating WNT signaling. Oncogene. 2022;41:2609\u201323.","journal-title":"Oncogene"},{"key":"8751_CR149","doi-asserted-by":"publisher","first-page":"8537","DOI":"10.1038\/s41598-018-26761-2","volume":"8","author":"K Han","year":"2018","unstructured":"Han K, Lang T, Zhang Z, Zhang Y, Sun Y, Shen Z, Beuerman RW, Zhou L, Min D. Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics. Sci Rep. 2018;8:8537.","journal-title":"Sci Rep"},{"key":"8751_CR150","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.bbrc.2016.05.017","volume":"474","author":"D Zhong","year":"2016","unstructured":"Zhong D, Zhang HJ, Jiang YD, Wu P, Qi H, Cai C, Zheng SB, Dang Q. Saikosaponin-d: A potential chemotherapeutics in castration resistant prostate cancer by suppressing cancer metastases and cancer stem cell phenotypes. Biochem Biophys Res Commun. 2016;474:722\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"8751_CR151","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ptr.6563","volume":"34","author":"M Zhu","year":"2020","unstructured":"Zhu M, Yu X, Zheng Z, Huang J, Yang X, Shi H. Capsaicin suppressed activity of prostate cancer stem cells by inhibition of Wnt\/\u03b2-catenin pathway. Phytother Res. 2020;34:817\u201324.","journal-title":"Phytother Res"},{"key":"8751_CR152","doi-asserted-by":"crossref","first-page":"117638","DOI":"10.1016\/j.taap.2025.117638","volume":"506","author":"R Rajadnya","year":"2026","unstructured":"Rajadnya R, Patil P, Deotare A, Mali A. Matairesinol regulates TGF-\u03b2-induced EMT and TGF-\u03b2 associated crosstalk with Wnt Signaling in PC3 prostate cancer cells: An omics-guided therapeutic insight. Toxicol Appl Pharmacol. 2026;506:117638.","journal-title":"Toxicol Appl Pharmacol"},{"key":"8751_CR153","doi-asserted-by":"crossref","first-page":"110216","DOI":"10.1016\/j.abb.2024.110216","volume":"762","author":"Y Xuan","year":"2024","unstructured":"Xuan Y, Xu J, Que H, Zhu J. Effects of sulforaphane on prostate cancer stem cells-like properties: In vitro and molecular docking studies. Arch Biochem Biophys. 2024;762:110216.","journal-title":"Arch Biochem Biophys"},{"key":"8751_CR154","doi-asserted-by":"crossref","first-page":"103912","DOI":"10.1016\/j.isci.2022.103912","volume":"25","author":"H Yonezawa","year":"2022","unstructured":"Yonezawa H, Ikeda A, Takahashi R, Endo H, Sugawara Y, Goto M, Kanno M, Ogawa S, Nakamura K, Ujiie H, et al. Ivermectin represses Wnt\/\u03b2-catenin signaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases. iScience. 2022;25:103912.","journal-title":"iScience"},{"key":"8751_CR155","doi-asserted-by":"crossref","first-page":"115071","DOI":"10.1016\/j.taap.2020.115071","volume":"401","author":"A Samy","year":"2020","unstructured":"Samy A, Bakthavachalam V, Vudutha M, Vinjamuri S, Chinnapaka S, Munirathinam G. Eprinomectin, a novel semi-synthetic macrocylic lactone is cytotoxic to PC3 metastatic prostate cancer cells via inducing apoptosis. Toxicol Appl Pharmacol. 2020;401:115071.","journal-title":"Toxicol Appl Pharmacol"},{"key":"8751_CR156","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/s41416-018-0110-1","volume":"118","author":"F Gao","year":"2018","unstructured":"Gao F, Alwhaibi A, Artham S, Verma A, Somanath PR. Endothelial Akt1 loss promotes prostate cancer metastasis via \u03b2-catenin-regulated tight-junction protein turnover. Br J Cancer. 2018;118:1464\u201375.","journal-title":"Br J Cancer"},{"key":"8751_CR157","doi-asserted-by":"crossref","first-page":"110015","DOI":"10.1016\/j.cellsig.2021.110015","volume":"84","author":"S Wu","year":"2021","unstructured":"Wu S, Yue Y, Gu Y, Wang Q, Liu T, Li L, Wang X, Chang LS, He D, Wu K. MUC15 loss facilitates epithelial-mesenchymal transition and cancer stemness for prostate cancer metastasis through GSK3\u03b2\/\u03b2-catenin signaling. Cell Signal. 2021;84:110015.","journal-title":"Cell Signal"},{"key":"8751_CR158","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1038\/s41598-019-41182-5","volume":"9","author":"D Stakheev","year":"2019","unstructured":"Stakheev D, Taborska P, Strizova Z, Podrazil M, Bartunkova J, Smrz D. The WNT\/\u03b2-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro. Sci Rep. 2019;9:4761.","journal-title":"Sci Rep"},{"key":"8751_CR159","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/sj.emboj.7601607","volume":"26","author":"W Luo","year":"2007","unstructured":"Luo W, Peterson A, Garcia BA, Coombs G, Kofahl B, Heinrich R, Shabanowitz J, Hunt DF, Yost HJ, Virshup DM. Protein phosphatase 1 regulates assembly and function of the beta-catenin degradation complex. Embo j. 2007;26:1511\u201321.","journal-title":"Embo j"},{"key":"8751_CR160","doi-asserted-by":"crossref","first-page":"22649","DOI":"10.1074\/jbc.M109.013698","volume":"284","author":"W Zhang","year":"2009","unstructured":"Zhang W, Yang J, Liu Y, Chen X, Yu T, Jia J, Liu C. PR55 alpha, a regulatory subunit of PP2A, specifically regulates PP2A-mediated beta-catenin dephosphorylation. J Biol Chem. 2009;284:22649\u201356.","journal-title":"J Biol Chem"},{"key":"8751_CR161","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1158\/1535-7163.MCT-16-0584","volume":"16","author":"S Maheshwari","year":"2017","unstructured":"Maheshwari S, Avula SR, Singh A, Singh LR, Palnati GR, Arya RK, Cheruvu SH, Shahi S, Sharma T, Meena S, et al. Discovery of a Novel Small-Molecule Inhibitor that Targets PP2A-\u03b2-Catenin Signaling and Restricts Tumor Growth and Metastasis. Mol Cancer Ther. 2017;16:1791\u2013805.","journal-title":"Mol Cancer Ther"},{"key":"8751_CR162","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s12032-023-02062-1","volume":"40","author":"R Serttas","year":"2023","unstructured":"Serttas R, Erdogan S. Pretreatment of prostate cancer cells with salinomycin and Wnt inhibitor increases the efficacy of cabazitaxel by inducing apoptosis and decreasing cancer stem cells. Med Oncol. 2023;40:194.","journal-title":"Med Oncol"},{"key":"8751_CR163","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13046-017-0595-0","volume":"36","author":"Y Liu","year":"2017","unstructured":"Liu Y, Chen H, Zheng P, Zheng Y, Luo Q, Xie G, Ma Y, Shen L. ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population. J Exp Clin Cancer Res. 2017;36:125.","journal-title":"J Exp Clin Cancer Res"},{"key":"8751_CR164","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1158\/0008-5472.CAN-17-3006","volume":"78","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Cheng L, Li J, Farah E, Atallah NM, Pascuzzi PE, Gupta S, Liu X. Inhibition of the Wnt\/\u03b2-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer. Cancer Res. 2018;78:3147\u201362.","journal-title":"Cancer Res"},{"key":"8751_CR165","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/0008-5472.CAN-20-3351","volume":"81","author":"K Unno","year":"2021","unstructured":"Unno K, Chalmers ZR, Pamarthy S, Vatapalli R, Rodriguez Y, Lysy B, Mok H, Sagar V, Han H, Yoo YA, et al. Activated ALK Cooperates with N-Myc via Wnt\/\u03b2-Catenin Signaling to Induce Neuroendocrine Prostate Cancer. Cancer Res. 2021;81:2157\u201370.","journal-title":"Cancer Res"},{"key":"8751_CR166","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1128\/MCB.01034-07","volume":"27","author":"T Fevr","year":"2007","unstructured":"Fevr T, Robine S, Louvard D, Huelsken J. Wnt\/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol. 2007;27:7551\u20139.","journal-title":"Mol Cell Biol"},{"key":"8751_CR167","doi-asserted-by":"crossref","first-page":"115708","DOI":"10.1016\/j.bone.2020.115708","volume":"143","author":"KE Lim","year":"2021","unstructured":"Lim KE, Bullock WA, Horan DJ, Williams BO, Warman ML, Robling AG. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration. Bone. 2021;143:115708.","journal-title":"Bone"},{"key":"8751_CR168","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0304-3940(96)12792-0","volume":"212","author":"BY Ho","year":"1996","unstructured":"Ho BY, Zhao J. Determination of the cannabinoid receptors in mouse x rat hybridoma NG108-15 cells and rat GH4C1 cells. Neurosci Lett. 1996;212:123\u20136.","journal-title":"Neurosci Lett"},{"key":"8751_CR169","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1074-7613(00)00004-2","volume":"13","author":"T Reya","year":"2000","unstructured":"Reya T, O\u2019Riordan M, Okamura R, Devaney E, Willert K, Nusse R, Grosschedl R. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity. 2000;13:15\u201324.","journal-title":"Immunity"},{"key":"8751_CR170","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41416-021-01389-8","volume":"125","author":"J Rodon","year":"2021","unstructured":"Rodon J, Argil\u00e9s G, Connolly RM, Vaishampayan U, de Jonge M, Garralda E, Giannakis M, Smith DC, Dobson JR, McLaughlin ME, et al. Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. Br J Cancer. 2021;125:28\u201337.","journal-title":"Br J Cancer"},{"key":"8751_CR171","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/oncolo\/oyad007","volume":"28","author":"J Tabernero","year":"2023","unstructured":"Tabernero J, Van Cutsem E, Garralda E, Tai D, De Braud F, Geva R, van Bussel MTJ, Fiorella Dotti K, Elez E, de Miguel MJ, et al. A Phase Ib\/II Study of WNT974\u2009+\u2009Encorafenib\u2009+\u2009Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. Oncologist. 2023;28:230\u20138.","journal-title":"Oncologist"},{"key":"8751_CR172","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-17-2157","volume":"23","author":"A Jimeno","year":"2017","unstructured":"Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, et al. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017;23:7490\u20137.","journal-title":"Clin Cancer Res"},{"key":"8751_CR173","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1158\/2767-9764.CRC-25-0502","volume":"5","author":"CH Lieu","year":"2025","unstructured":"Lieu CH, Lenz HJ, Benson AB, Meng X, Kim UI, Kim SH, Kim K, Sung MJ. A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors. Cancer Res Commun. 2025;5:1771\u20138.","journal-title":"Cancer Res Commun"},{"key":"8751_CR174","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1073\/pnas.0810956106","volume":"106","author":"A Dubrovska","year":"2009","unstructured":"Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garc\u00eda-Echeverr\u00eda C, Schultz PG, Reddy VA. The role of PTEN\/Akt\/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A. 2009;106:268\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8751_CR175","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1158\/0008-5472.CAN-13-0874","volume":"73","author":"P Kroon","year":"2013","unstructured":"Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, Bhasin D, Chettiar S, Li C, Li PK, et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 2013;73:5288\u201398.","journal-title":"Cancer Res"},{"key":"8751_CR176","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1038\/onc.2014.215","volume":"34","author":"EJ Yun","year":"2015","unstructured":"Yun EJ, Baek ST, Xie D, Tseng SF, Dobin T, Hernandez E, Zhou J, Zhang L, Yang J, Sun H, et al. DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1. Oncogene. 2015;34:2741\u201352.","journal-title":"Oncogene"},{"key":"8751_CR177","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/cam4.675","volume":"5","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Jin Z, Zhou H, Ou X, Xu Y, Li H, Liu C, Li B. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Med. 2016;5:1251\u20138.","journal-title":"Cancer Med"},{"key":"8751_CR178","doi-asserted-by":"crossref","first-page":"113704","DOI":"10.1016\/j.jconrel.2025.113704","volume":"382","author":"Y Qu","year":"2025","unstructured":"Qu Y, Guo B, Zhao S, Sun J, Cao J, Xia M, Zhong Z, Meng F. Photothermal treatment of prostate tumor with micellar indocyanine green and napabucasin to co-ablate cancer cells and cancer stem cells. J Control Release. 2025;382:113704.","journal-title":"J Control Release"},{"key":"8751_CR179","doi-asserted-by":"crossref","first-page":"iii150","DOI":"10.1093\/annonc\/mdx302.001","volume":"28","author":"T Bekaii-Saab","year":"2017","unstructured":"Bekaii-Saab T, Starodub A, El-Rayes B, O\u2019Neil B, Shahda S, Ciombor K, Noonan A, Hanna W, Sehdev A, Shaib W, et al. A phase 1b\/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts). Ann Oncol. 2017;28:iii150.","journal-title":"Ann Oncol"},{"key":"8751_CR180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C, Matsubara N, Alekseev B, Parnis F, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021;398:131\u201342.","journal-title":"Lancet"},{"key":"8751_CR181","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","volume":"26","author":"RR Aggarwal","year":"2020","unstructured":"Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, et al. A Phase Ib\/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2020;26:5338\u201347.","journal-title":"Clin Cancer Res"},{"key":"8751_CR182","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cmet.2019.05.004","volume":"30","author":"G Civenni","year":"2019","unstructured":"Civenni G, Bosotti R, Timpanaro A, V\u00e0zquez R, Merulla J, Pandit S, Rossi S, Albino D, Allegrini S, Mitra A, et al. Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer. Cell Metab. 2019;30:303\u2013e318306.","journal-title":"Cell Metab"},{"key":"8751_CR183","doi-asserted-by":"crossref","first-page":"19191","DOI":"10.1074\/jbc.M309560200","volume":"279","author":"TR Salas","year":"2004","unstructured":"Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, et al. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem. 2004;279:19191\u2013200.","journal-title":"J Biol Chem"},{"key":"8751_CR184","doi-asserted-by":"crossref","first-page":"30935","DOI":"10.1074\/jbc.M201919200","volume":"277","author":"M Sharma","year":"2002","unstructured":"Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase\/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem. 2002;277:30935\u201341.","journal-title":"J Biol Chem"},{"key":"8751_CR185","first-page":"1215","volume":"2","author":"X Liao","year":"2003","unstructured":"Liao X, Zhang L, Thrasher JB, Du J, Li B. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther. 2003;2:1215\u201322.","journal-title":"Mol Cancer Ther"},{"key":"8751_CR186","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/0008-5472.CAN-07-6362","volume":"68","author":"R Ven\u00e8","year":"2008","unstructured":"Ven\u00e8 R, Larghero P, Arena G, Sporn MB, Albini A, Tosetti F. Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids. Cancer Res. 2008;68:6987\u201396.","journal-title":"Cancer Res"},{"key":"8751_CR187","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.7150\/thno.78915","volume":"13","author":"JM White","year":"2023","unstructured":"White JM, Ramos N, Saliganan AD, Chung JY, Bell M, Lindquist J, Conner K, Wiesend WN, Schopperle M, Patrick SM, et al. Selective ablation of TRA-1-60(+) pluripotent stem cells suppresses tumor growth of prostate cancer. Theranostics. 2023;13:2057\u201371.","journal-title":"Theranostics"},{"key":"8751_CR188","doi-asserted-by":"crossref","first-page":"e42564","DOI":"10.1371\/journal.pone.0042564","volume":"7","author":"J Jiao","year":"2012","unstructured":"Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, Chen D, Li Y, Guo C, Zhang B, et al. Identification of CD166 as a surface marker for enriching prostate stem\/progenitor and cancer initiating cells. PLoS ONE. 2012;7:e42564.","journal-title":"PLoS ONE"},{"key":"8751_CR189","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang S, Li H, Zhang L, Mu W, Zhang Y, Chen T, Wu J, Tang H, Zheng S, Liu Y, et al. Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 2025;53:D1670\u20136.","journal-title":"Nucleic Acids Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08751-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08751-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08751-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:34:34Z","timestamp":1791668074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08751-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":189,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8751"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08751-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1279"}}